Celldex Therapeutics shares are trading lower. The company announced 52 week results from its Barzolvolimab Phase 2 Study in chronic spontaneous urticaria at EADV 2024.
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics shares declined following the announcement of 52-week results from its Barzolvolimab Phase 2 Study in chronic spontaneous urticaria at EADV 2024.
September 25, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Celldex Therapeutics shares fell after the company announced results from its Barzolvolimab Phase 2 Study in chronic spontaneous urticaria at EADV 2024. The market reaction suggests the results may not have met investor expectations.
The decline in Celldex Therapeutics' stock price indicates that the market was not satisfied with the 52-week results of the Barzolvolimab Phase 2 Study. This suggests that the results may not have met investor expectations, leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100